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ABSTRACT
The aim of this study was to evaluate whether patients with type 2 diabetes (T2D) who had 
stopped attending their diabetes treatment system (referred to as “lost to follow-up”, LTF) but 
who succeeded in improving their glycaemic control after returning to the diabetes treatment 
system had changes in their diabetes medication when compared with similar patients who did 
not show improvement. “LTFs” who had baseline haemoglobin A1 c (HbA1 c) ≥53 mmol/mol and 
succeeded in reducing HbA1 c ≥ 6 mmol/mol during a 12–30 month follow-up period after 
adhering again to their diabetes treatment system were compared with “LTFs” who had an 
unsatisfactory change in HbA1 c or with “LTFs” who maintained good glycaemic control through-
out the 12–30 month follow-up period. Unsatisfactory change in HbA1 c was determined as HbA1  
c ≥ 53 mmol/mol and change <6 mmol/mol after the 12–30 month follow-up period in their 
diabetes treatment system or HbA1 c < 53 mmol/mol when returning to the diabetes treatment 
system but ≥53 mmol/mol at the end of the 12–30 month follow-up period. “LTFs” with 
improvement in glycaemic control used a higher number of different anti-hyperglycaemic agents 
(P < 0.001) and their dosages of metformin increased (P < 0.05) when compared with “LTFs” 
without improvement or “LTFs” with satisfactory glycaemic control. Cholesterol-, LDL-cholesterol- 
and triglyceride-concentrations decreased during the 12–30 month follow-up period (P < 0.05) in 
“LTFs” with improved glycaemic control, but not in the other groups. “LTFs” with T2D who had 
poor glycaemic control seemed to require an increase in their anti-diabetic medication when 
attempting to improve their glycaemic control.
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Introduction
A proportion of patients with type 2 diabetes (T2D) do 
not attend diabetes clinics as prescribed by the health- 
care personnel for a variety of reasons. Poor adherence 
may be linked to the type of care provided, demo-
graphic factors, patients beliefs to medication, and per-
ceived patient burden regarding the treatment 
procedures [1]. Especially in young patients’ inadequate 
glycaemic control can be explained with poor adher-
ence to medication [2]. These “LTFs” may be exposed to 
a notable risk of diabetic complications thus reducing 
their quality of life and raising the costs of diabetes 
treatment [3–5]. Very little is known about what hap-
pens when “LTFs” are recruited back into the T2D treat-
ment system in primary care.
Previous study findings have shown that in the pub-
lic primary health-care system, 1 in 10 patients with T2D 
is an “LTF” [4]. Although “LTFs” with T2D are generally 
difficult to bring back into the system, those with poor 
glycaemic control and who are successfully re-attached 
to the diabetes treatment system seem to benefit from 
being recalled [5]. Further, this subgroup of “LTFs” with 
T2D seems to benefit, at least glycaemic control 
improves, from intensive communication and counsel-
ling with the health-care professionals [6]. However, it is 
unknown whether there are any differences in the 
changes in diabetes medication between “LTFs” who 
improved their glycaemic control and those who 
did not.
Parameters such as blood pressure (BP) and lipid 
concentrations may also affect, even independently, 
the wellbeing and cardiovascular outcomes of patients 
with T2D [7–10]. How these parameters are affected 
when glycaemic control is improved is unknown.
The aim of the study was to compare the changes 
made to the diabetes medication in “LTFs” with T2D 
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after re-attaching to the diabetes treatment system. As 
a secondary outcome, we examined whether there 
were differences in other studied parameters than gly-
cosylated haemoglobin A1 c (HbA1 c) between “LTFs” 
with or without an improvement in glycaemic control.
Materials and methods
Study design and setting
This study was a “real-life” longitudinal observational 
register-based cohort study using data retrospectively 
obtained from an electronic patient record system. In 
2009, a project was initiated for improving the glycae-
mic control of those who did not attend to T2D care 
system in the public primary healthcare in the city of 
Vantaa, Finland. We recorded retrospectively the influ-
ence of the clinical work performed by the community 
primary health-care nurses and general practitioners [4].
The ethics committee of the Hospital District of 
Helsinki and Uusimaa (Nr 91/13/03/01/2011, 9.1.2013) 
and the health authority of the city of Vantaa (Dno 
SOSTER 3124/2011/092) approved this study. 
According to the ethics committee of the Hospital 
District of Helsinki and Uusimaa, and health authority 
of Vantaa, the study participants did not need to sign 
a Statement of Informed Consent because the study 
was retrospective, based on patient charts and the 
investigators did not contact the “LTFs”.
Study participants
Data collected for the study were based on clinical 
patient records obtained from the public primary 
healthcare of the eastern districts of Vantaa, Finland. 
At the time of the study, Vantaa had a population of 
195 397 inhabitants and the eastern districts had 118 
802 inhabitants. We identified all patients aged 
18–80 years. Patients were determined to have T2D if 
they had an International Classification of Disease (ICD- 
10) code E11 in the patient charts or they were pre-
scribed specific anti-hyperglycaemic agents for T2D 
between 1 January 2005 and 31 December 2009. In 
Finland, the public primary healthcare used ICD-10 
codes to classify diseases, health related disorders, inju-
ries, infections, and symptoms. A computer-based 
search was made from Finstar (Logica, Helsinki, 
Finland) patient chart system with a specific report 
generator.
In the eastern districts of Vantaa, 3459 people ful-
filled the criteria of having T2D. Patients who fulfilled 
T2D criteria but had not contacted the public primary 
health-care system during the previous 12 months 
(during 2009) were considered “LTFs” [4]. To establish 
whether these “LTFs” were true “LTFs” or whether they 
were receiving treatment elsewhere (e.g. whether they 
were receiving treatment arranged in another system, 
private or secondary care), trained diabetes nurses from 
the public primary health-care system contacted them 
by phone. If an “LTF” was a true “LTF”, trained diabetes 
nurses booked an appointment including laboratory 
tests (baseline visit, n = 356 [4]) in order to improve 
the diabetes treatment and to bring the “LTF” back to 
the public primary health-care system. In Finland in that 
time point, systemic call-back attempts by nurses or 
diabetes nurses have not been part of the usual public 
primary healthcare The follow-up visit was the nearest 
visit taking place at least one year after the initial visit 
(12 to 30 months after the baseline visit). Of the con-
tacted true “LTFs”, 32% (n = 115) participated both in 
the baseline visit and the follow-up visit [5] and com-
posed the study population of the study. Figure 1 
shows the flowchart of the study.
Study procedures
At the baseline visit the participant’s status was 
assessed, blood was drawn and diabetes counselling 
was provided, and treatment was enhanced when 
needed [4]. The follow-up visit included the same 
assessments as the baseline visit. Based on the HbA1 c 
measured at the follow-up visit, the success of treat-
ment was evaluated.
“LTFs” were divided into three groups according to 
their glycaemic control at the baseline visit and at the 
follow-up visit. One group was defined as “LTFs” with 
an improvement in glycaemic control, e.g. those who 
had a HbA1 c level ≥53 mmol/mol (7%) at the baseline 
visit and a reduction in HbA1 c ≥ 6 mmol/mol (0.5%) at 
the follow-up visit 12–30 months later [6]. The second 
group was defined as “LTFs” without improvement, e.g. 
those who had a HbA1 c level ≥53 mmol/mol (7%) at 
the baseline visit and the decrease of HbA1 c level was 
<6 mmol/l (0.5%) or ”LTFs” who had a HbA1 c level 
<53 mmol/mol (7%) at the baseline visit but more 
than that at the follow-up visit 12–30 months later [6]. 
The third group was defined as “LTFs” with good gly-
caemic control, e.g. those who had a HbA1 c level 
<53 mmol/mol (7%) and the HbA1 c level remained 
under this value during the 12–30 months follow-up 
time [4]. According to international guidelines and epi-
demiological studies [11–14] diabetic complications 
increase significantly if the HbA1 c level is <53 mmol/ 
mol (7%). Therefore, this level was chosen as an indica-
tor of good glycaemic control. The level of change in 
HbA1 c (6 mmol/mol, 0.5%) was chosen because 
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previous studies have shown that reducing HbA1 c by 
this amount reduces the incidence of complications in 
T2D [11,12]. In those patients who returned to the 
public primary health-care system diabetes treatment 
was provided according to national and international 
guidelines, including yearly laboratory, nurse and doc-
tor controls and, if needed, optimising medications 
[13,14].
Primary and secondary outcomes
Trained diabetes nurses collected data from the patient 
records on diabetes medication before and after the 
12–30 month follow-up. Based on the medication 
data, the recruited ”LTFs” were divided into two groups: 
those who were prescribed higher doses of diabetes 
medication or an increased number of diabetes drugs 
at the follow-up visit (increased medication), and those 
who had no changes or who were moved from one oral 
diabetes medication to another (no change in 
medication).
As secondary outcomes, we studied patient charac-
teristics including sex, baseline body mass index (BMI), 
duration of diabetes, diagnosed retinopathy or albumi-
nuria. Baseline BP, blood lipids (cholesterol, low density 
lipoprotein [LDL] -cholesterol, high density lipoprotein 
[HDL] -cholesterol, triglycerides), haemoglobin, alanine 
transaminase, creatinine and prevalence of proteinuria 
were recorded. When data were available BP, choles-
terol, LDL-cholesterol, HDL-cholesterol, triglycerides, 
creatinine and prevalence of proteinuria were recorded 
and compared with the respective baseline status in all 
three groups of glycaemic control.
Statistical analysis
Data are presented as percentage (n) or mean (standard 
deviation, [SD]) or median (interquartile range [IQR] 
25%-75%). Prevalence differences were tested using 
cross-tabulation and Chi-Square test. Magnitude differ-
ences were analysed with Kruskal-Wallis analysis of var-
iance followed by Dunns’ method or ANOVA followed 
by Bonferroni corrected t-test. Comparisons between 
before-after situations were carried out with paired 
t-test, Wilcoxon signed rank-test or cross-tabulation 
and Chi-Square test when applicable. A P-value <0.05 
was considered statically significant.
Results
Characteristics of the study participants at baseline
At the baseline visit, BMI was higher in “LTFs” with 
improved glycaemic control than in the other groups. 
At the baseline visit, “LTFs” with improvements had 
higher triglyceride and lower HDL-cholesterol concen-
trations than those who maintained good glycaemic 
control (Table 1). Table 1 shows the characteristics of 
the study participants at the baseline visit. “LTFs” with-
out improvement had a longer duration of T2D than 
those who had good glycaemic control (Table 2).
Diabetes medication
An increase in dosage or in the number of different T2D 
drugs during the follow-up was higher in “LTFs” with 
improvements (32/36, e.g. 89%) than in those without 
improvement in glycaemic control (17/27, e.g. 63%, 
P < 0.05) or those with good glycaemic control (16/52, 
Figure 1. Flow chart of the study.
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e.g. 31%, P < 0.001). “LTFs” without improvement also 
had more increases in their medication than those with 
good glycaemic control (P < 0.05). There was an 
increase in the use of DPP-4 (dipeptidyl peptidase 4)- 
inhibitors in all studied groups (Table 2). At the baseline 
visit, the groups did not differ in the dosage of metfor-
min used. The dosage of metformin increased in “LTFs” 
with improvements from 1000 mg (median, IQR 
25–75%: 0–2500 mg) to 2000 mg (1500–3000 mg, 
P < 0.05) but not in those without improvement (from 
Table 1. Characteristics of the study participants (loss of follow-ups, LTFs) at baseline.a.
Glycaemic controlb
LTFs with improvementc 
n = 36
Without improvementb 
n = 27
Good controlc 
n = 52
Males 16 (44%) 11 (41%) 26 (50%)
Duration of T2D (yrs) 6.5 (IQR25-75%; 3.25–10) 10 (6–10)### 4 (2–8, n = 48)
BMI (kg/mb) 33.6 (IQR25-75%:30.6–38.9, n = 29) 30.1 (26.7–32.9, n = 19)* 31.3 (27.2–35.1, n = 39)*
Chlolesterol (mmol/l) 4.8 (IQR25-75%:4.2–5.56, n = 34) 4.7 (3.98–5.75, n = 26) 4.8 (3.7–5.6, n = 51)
LDL-cholesterol (mmol/l) 2.8 (IQR25-75%:2.2–3,43, n = 34 2.8 (2.15–3.33, n = 26) 2.6 (2.0–3.4, n = 51)
HDL-cholesterol (mmol/l) 1.18 (IQR25-75%:0.95–1.33 n = 32) 1.20 (1.10–1.40, n = 26) 1.33 (1.15–1.80, n = 51)*
Triglycerides (mmol/l) 2.2 (IQR25-75%:1.5–3.2, n = 32) 2.1 (1.0–2.5, n = 26) 1.3 (1.1–2.0, n = 51)*
Haemoglobin (g/l) 150.4 (SD:11.5, n = 32) 143.7 (15.3, n = 24) 140.5 (12.8, n = 50)*
Alanine transaminase (U/l) 38.0 (IQR25-75%:25.0–84.5, n = 21) 27.0 (16.3–51.0, n = 12) 28.0 (20.0–33.0, n = 25)
Microalbuminuria (µg/min) 4.5 (IQR25-75%:2.3–25.5, n = 28) 6.0 (2.0–42.5, n = 21) 3.0 (2.0–6.0, n = 47)
Creatinine (μmol/l) 59.0 (IQR25-75%:53.0–72.5, n = 32) 66.0 (62.0–84.0, n = 21) 69.0 (61.0–85.3, n = 48)
Systolic blood pressure (mmHg) 143 (SD:21, n = 30) 149 (22, n = 22) 149 (22, n = 42)
Diastolic blood pressure (mmHg) 90 (SD:11, n = 30) 88 (SD:11, n = 22) 86 (SD:10, n = 42)
Retinopathy 7/27 (26%) 7/23 (30%) 11/35 (31%)
Albuminuria 6/29 (21%) 7/21 (33%) 5/47 (10%)
SD = standard deviation; IQR = inter quartile range; T2D = type-2 diabetes; BMI = body mass index; LDL = low density lipoprotein; HDL = high density 
lipoprotein. 
aIf results are expressed as median and Inter-Quartile Range25-75% Kruskal–Wallis analysis of variance followed with Dunns’ method was used. If results are 
expressed as mean and Standard Deviation ANOVA followed by Bonferroni method was used. * stands for P < 0.05 vs. LTFs with improvement Bonferroni 
method and ### stands for P < 0.001 vs. good control group, Dunns’ method. 
bNumber (n) of available measurements in different glycaemic groups is expressed in the parentheses. 
cLTFs with improvement: LTFs who had a HbA1 c level ≥53 mmol/mol (7%) at the baseline visit and a reduction in HbA1 c ≥ 6 mmol/mol (0.5%) at the follow- 
up visit 12–30 months later; bLTFs without improvement: LTFs who had a HbA1 c level ≥53 mmol/mol (7%) at the baseline visit and the decrease of HbA1 c 
level was <6 mmol/l (0.5%) or LTFs who had a HbA1 c level <53 mmol/mol (7%) at the baseline visit but more than that at the follow-up visit 
12–30 months later; cGood control: LTFs who had a HbA1 c level <53 mmol/mol (7%) and the HbA1 c level remained under this value during the 
12–30 months follow-up time. 
Table 2. Number of loss of follow-ups (LTFs) using a specific type of anti-hyperglycaemic agent at the baseline and at 
the follow-up visit.
LTFs with improvementa 
n = 36 Number of participants at the baseline visit
Number of participants at the 
follow-up visit
Metformin 24 31
Insulin 7 11
Glitazones 2 4
DPP-4-inhibitors 1 14*
Sulphonylureas 12 7
LTFs without improvementb 
n = 27
Metformin 25 26
Insulin 3 7
Glitazones 7 6
DPP-4-inhibitors 1 7*
Sulphonylureas 7 3
Good controlc 
n = 52
Metformin 24 31
Insulin 7 11
Glitazones 2 4
DPP-4-inhibitors 2 12*
Sulphonylureas 12 7
DPP-4 = dipeptidyl peptidase 4. 
aLTFs with improvement: LTFs who had a HbA1 c level ≥53 mmol/mol (7%) at the baseline visit and a reduction in HbA1 c ≥ 6 mmol/mol (0.5%) 
at the follow-up visit 12–30 months later; bLTFs without improvement: LTFs who had aHbA1 c level ≥53 mmol/mol (7%) at the baseline visit 
and the decrease of HbA1 c level was <6 mmol/l (0.5%) and such LTFs who had a HbA1 c level <53 mmol/mol (7%) at the baseline visit but 
more than that at the follow-up visit 12–30 months later; cGood control: LTFs who had a HbA1 c level <53 mmol/mol (7%) and the HbA1 c 
level remained under this value during the 12–30 months follow-up time. 
* stands for P < 0.05 vs. baseline status, Χ2-test 
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2050 ± 960 mg [mean±SD] to 1956 ± 878 mg) or in 
those whose glycaemic control remained good (from 
1298 ± 1197 mg to 1432 ± 1042 mg). No other sys-
tematic changes in medication were observed during 
the follow-up (Table 2).
Changes in different parameters during follow-up 
in different glycaemic control groups
About half (23–30/52) of the “LTFs” who remained in 
good glycaemic control also underwent other labora-
tory tests and BP checks than HbA1 c. Roughly one third 
of those “LTFs” who were not in optimal glycaemic 
control at baseline but showed improvement (9–16/ 
36) or who showed no improvement (10–16/27) parti-
cipated in the T2D check-ups during the follow-up 
period. In “LTFs” with improvement and who partici-
pated in these check-ups, total cholesterol, LDL- 
cholesterol and triglyceride concentrations decreased 
(Table 3).
Discussion
Improved glycaemic control in recruited “LTFs” was asso-
ciated with increases in both dosage and the number of 
drugs used for T2D treatment. There seemed to be 
changes in medications, especially an increase in the 
use of DPP4-inhibitors, even among those “LTFs” with 
good glycaemic control during the follow-up. The labora-
tory follow-ups were generally performed unsatisfactorily 
and good clinical care guidelines [13,14] were not fol-
lowed adequately. A longer duration of T2D was asso-
ciated with worse glycaemic control. Non-optimal lipid 
status seemed to improve if a “LTF” was able to improve 
his/her glycaemic control during follow-up.
Among participants with improvement in glycaemic 
control, the main change was an increase in the number 
Table 3. Change in different parameters during the 12–30 month follow-up period in different glycaemic control groups of loss of 
follow-ups (LTFs).a.
LTFs with improvementc 
n = 36 At the baseline visit At the follow-up visit
Weight (n = 9, kg)b 100.8 (SD:16.5) 96.1 (16.2)
Cholesterol (n = 12, mmol/l) 5.1 (IQR25-75%:3.8–6.1) 4.4 (3.2–4.9)**
LDL-Cholesterol (n = 12, mmol/l) 3.3 (IQR25-75%:2.0–3.6) 2.6 (1.7–3.1)**
HDL-Cholesterol (n = 11, mmol/l) 1.3 (IQR25-75%:0.8–1.5) 1.3 (1–1.4)
Triglycerides (n = 11, mmol/l) 2.2 (SD:0.8) 1.7 (0.8)*
Microalbuminuria (n = 13, µg/min) 5.0 (IQR25-75%:2.5–29.5) 8.0 (3.0–55.5)
Creatinine (n = 16, μmol/l) 70.2 (SD:20.9) 70.4 mg/l (18.4)
Systolic BP (n = 8, mmHg) 146 (SD:19) 140 (13)
Diastolic BP (n = 8, mmHg) 90 (SD:13) 82 (10)
LTFs without improvementb 
n = 27
Weight (n = 10, kg) 94.0 (SD:17) 93.2 (16.4)
Cholesterol (n = 16, mmol/l) 4.9 (SD:1.3) 4.6 (1.0)
LDL Cholesterol (n = 16 mmol/l) 3 mmol/l (SD:1) 2.8 (0.8)
HDL-Cholesterol (n = 16, mmol/l) 1.1 mmol/l (IQR25-75%:0.9–1.3) 1.1 (0.9–1.3)
Triglycerides (n = 16, mmol/l) 1.9 mmol/l (IQR25-75%:1.3–3) 1.7 (1.3–2.6)
Microalbuminuria (n = 11 µg/min) 4.0 (IQR25-75%:2.0–18.0) 2.0 (2.0–18.0)
Creatinine (n = 14, μmol/l) 65.4 (SD:17.3) 73.2 (18.4)*
Systolic blood pressure (n = 12, mmHg) 137 (SD:22.0) 137 (23)
Diastolic blood pressure (n = 12, mmHg) 88 (SD:11) 81 (10)
Good controlc 
n = 52
Weight (n = 23, kg) 97.5 (SD:24.9) 96.8(25.3)
Cholesterol (n = 29, mmol/l) 4.8 (SD:1.0) 4.6 (1.1)
LDL Cholesterol (n = 30, mmol/l) 2.9 (SD:0.9) 2.6 (SD:0.9)
HDL-Cholesterol (n = 30, mmol/l) 1.2 (IQR25-75%:1.1–1.5) 1.2 (1.0–1.5)
Triglycerides (n = 30, mmol/l) 1.8 (IQR25-75%:1.3–2.3) 1.7 (1.1–2.7)
Microalbuminuria (n = 19, µg/min) 6.0 (IQR25-75%:2.0–25.0) 8.0 (3.0–29.0)
Creatinine (n = 27, μmol/l) 67.4 (SD: 17.5) 72.4 (20.8)**
Systolic blood pressure (n = 23, mmHg) 156 (SD 21) 148 (20)
Diastolic blood pressure (n = 23, mmHg) 91 (SD 11) 86 (12)*
SD = standard deviation; IQR = inter quartile range; T2D = type-2 diabetes; BMI = body mass index; LDL = low density lipoprotein; HDL = high density 
lipoprotein. 
aIf results are expressed as median and Inter-Quartile Range25-75% Wilcoxon signed rank-test was used. If results are expressed as mean and Standard 
Deviation paired t-test was used. * stands for p < 0.05 and ** for P < 0.01 vs. before status, paired t-test or Wilcoxon signed-rank test. 
bNumber (n) of available measurements in different glycaemic groups is expressed in the parentheses. 
cLTFs with improvement: LTFs who had a HbA1 c level ≥53 mmol/mol (7%) at the baseline visit and a reduction in HbA1 c ≥ 6 mmol/mol (0.5%) at the follow- 
up visit 12–30 months later; bLTFs without improvement: LTFs who had a HbA1 c level ≥53 mmol/mol (7%) at the baseline visit and the decrease of HbA1 c 
level was <6 mmol/l (0.5%) and such LTFs who had a HbA1 c level <53 mmol/mol (7%) at the baseline visit but more than that at the follow-up visit 
12–30 months later; cGood control: LTFs who had a HbA1 c level <53 mmol/mol (7%) and the HbA1 c level remained under this value during the 
12–30 months follow-up time. 
INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH 5
of anti-hyperglycaemic agents prescribed as well as an 
increase in the dosage of metformin which was not 
observed in the other two groups. Yet there was no 
difference in the dosage of metformin between the 
groups at the beginning of the follow-up and therefore 
we cannot claim that there would have been a systematic 
underuse of this drug at the beginning of the follow-up in 
any of the groups studied. According to international and 
national diabetes treatment guidelines, which Finnish 
public primary care is supposed to follow [13,14] metfor-
min is the first-line medication in the treatment of T2D if 
contraindications do not inhibit its use [15]. Metformin 
has been shown to improve the prognosis of T2D patients 
[16]. The increasing communication, and thereby increas-
ing exchange of information, between the T2D treatment 
system and the recruited “LTFs” with improved glycaemic 
control which we observed [6] did not solely explain the 
improved glycaemic status. Recommendation based [13– 
15] increases in medication also seemed to be required for 
favourable results in T2D treatment of the “LTFs”.
Interestingly, use of DPP-4-inhibitors increased in 
all of the groups during the follow-up. Therefore, we 
cannot conclude that taking these preparations into 
the treatment repertoire would have hadst a general 
positive effect on the glycaemic status of the studied 
“LTFs”. The DPP-4-inhibitors also belong to the 
recommended second-line T2D-medications [13–15]. 
Yet nothing has been shown to be superior to met-
formin [15,16]. We were not able to show an associa-
tion between improvement in glycaemic control and 
an increase in the use of DPP-4-inhibitors so the main 
reason for the observed increased use of this type of 
medication may have been aggressive marketing. Just 
at the time of this study, DPP-4-inhibitors were novel 
preparations and they were strongly marketed. This 
may have been the reason for initiating DPP-4-inhibi-
tors as additive medication or replacing parts of pre-
vious medication with DPP-4-inhibitors, even in 
patients with good glycaemic control.
Actions which improved glycaemic control in those 
recruited “LTFs” who were able to improve their glycae-
mic control may also have induced modest improvements 
in some other parameters which are related to better 
vascular outcomes in T2D patients [8–10]. However, it is 
difficult to draw very strong conclusions about this 
because although the general practitioners followed 
good clinical care guidelines and monitored HbA1 c- 
concentrations as recommended [13–15] there were 
other vital parameters which were not as well monitored 
during the follow-up. Marking T2D diagnosis on patient 
charts does not guarantee that T2D is properly treated 
[17] and neglecting actions which belong to proper T2D 
treatment is not uncommon in primary care [18–20]. We 
had difficulties in getting follow-up data about physical 
measurements such as weight and BP although these 
parameters may have prognostic value for T2D patients 
[21]. This holds true also with certain laboratory tests 
which also may have similar value in the treatment of 
these patients [21]. Furthermore, the number of eligible 
patients was small. The present data are 10 years old. 
According to recent Finnish epidemiological studies [22], 
the prevalence of T2D has not, however, decreased since 
the times of these data were collected [23]. Slight changes 
in recommendations for treatment have been made since 
that time [13,14]. This could mean that a bigger propor-
tion of putative “LTFs” who finally attend to treatment 
could nowadays be helped to yield better glycaemic con-
trol than was possible in 2010–2012. Yet, this does not 
rule out the fact that the present data call for better 
adherence to T2D treatment guidelines in primary care.
Conclusions
Improved glycaemic control in recruited “LTFs” was 
associated with increases in metformin dosage and 
use of other diabetes medications. Improved medica-
tion combined with previously described increase in 
contacting the public primary care that improved gly-
caemic control may also have induced improvements in 
some other parameters related to better cardiovascular 
outcomes in T2D patients.
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